Publications by authors named "F Sakamaki"
Atezolizumab, an immune checkpoint inhibitor (ICI), was used in a phase III clinical trial, i.e., the OAK trial, of previously treated patients with non-small cell lung cancer.
View Article and Find Full Text PDFArticle Synopsis
- - Non-invasive evaluation of pulmonary blood flow is crucial for Understanding gas exchange in the lungs, and a chest digital dynamic radiography system (CDDR) can provide visual and quantitative data by capturing changes in lung radiographic transparency in sync with the heartbeat.
- - The lung-diffusing capacity (DLCO) test assesses factors related to the alveolar membrane and blood flow, and changes in DLCO can indicate variations in pulmonary blood flow, especially in patients with conditions like anaemia or without visible interstitial abnormalities.
- - The study compared CDDR results with DLCO measurements among patients categorized by their DLCO levels, revealing that the mean and median pulmonary blood flow values obtained through CDDR were significantly lower in those with reduced DLCO,
Article Synopsis
- Recent guidelines recommend against using PAH-targeted therapies in patients with pulmonary hypertension (PH) linked to respiratory diseases, highlighting the need for better assessment of treatment effectiveness.
- The study analyzed 270 patients with precapillary PH, categorizing them into severe and mild cases to evaluate the impact of initial treatments on their prognosis.
- Findings indicated that patients with severe PH and mild ventilatory impairment who received initial treatment showed a significantly better response and prognosis compared to those who did not, while such benefits were not seen in mild PH cases.
Article Synopsis
- TM5614, an inhibitor targeting plasminogen activator inhibitor (PAI)-1, showed potential benefits by reducing thrombosis, inflammation, and fibrosis in mouse models.
- In a trial with 26 Japanese COVID-19 patients, TM5614 was administered daily, resulting in all patients being discharged without significant side effects.
- A larger, randomized trial planned for 100 patients enrolled only 75, showing TM5614's effects on oxygenation and days of oxygen use were minimal compared to placebo, indicating the need for further research on its efficacy for treating COVID-19 pneumonia.